Members of the intracellular lipid-binding protein (iLBP) family, fatty acid-binding proteins (FABPs) transport intracellular hydrophobic ligands between cellular compartments like the peroxisomes, mitochondria, endoplasmic reticulum, and nucleus. FABPs are capable of binding long-chain (C16-C20) fatty acids, eicosanoids, bile salts, and peroxisome proliferators, demonstrating their broad specificity. FABPs exhibit strong evolutionary conservation and are found in a variety of species, including Caenorhabditis elegans, mouse, and humans as well as Drosophila melanogaster.
FABPs have a widespread expression in the body and are crucial to many physiological processes, including lipid metabolism, inflammation, and neuronal signaling. The endogenous cannabinoid arachidonoyl ethanolamide (AEA), as well as catabolism by the endoplasmic reticulum-localized enzyme fatty acid amide hydrolase (FAAH), have been shown to be transported intracellularly by FABPs of the mammalian central and peripheral nervous systems.
There are 12 different FABP subtypes produced by most mammals, but humans can produce up to 10. These include liver-(L-FABP, FABP1), intestine-(I-FABP, FABP2), heart-(H-FABP, FABP3), adipocyte-(A-FABP, FABP4), epidermal-(E-FABP, FABP5), ileal-(Il-FABP, FABP6), brain-(B-FABP, FABP7), myelin-(M-FABP, FABP8), testis-(T-FABP, FABP9) and FABP12, and three of which are expressed in the brain, including FABP3, FABP5 and FABP7.
FABPs play a variety of distinct and well-defined roles in controlling the metabolism and behavior of the ligands they bind. They are significant therapeutic and drug development targets for a variety of metabolic diseases.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V89012 | ART26.12 | 2766800-24-0 | ART26.12 is an orally active, selective inhibitor of FABP5. | |
V3484 | BMS-309403 | 300657-03-8 | BMS-309403 is a novel, potent, selective and cell-permeable inhibitor of fatty acid binding protein 4 (FABP4) with aKiof less than 2 nM. | |
V74007 | BMS-309403 sodium | 2802523-05-1 | BMS-309403 sodium is a potent and specific adipocyte fatty acid binding protein aFABP, also known as FABP4, aP2 inhibitor. | |
V74008 | CooP | 1192864-27-9 | CooP is a linear glioblastoma-targeting nonapeptide. | |
V74009 | FABP-IN-2 | 1426533-99-4 | FABP-IN-2 is a novel FABP3 ligand. | |
V87425 | FABP1-IN-1 | FABP1-IN-1 (44) is a selective FABP1 inhibitor with IC50 of 4.46 μM. | ||
V79372 | FABP4-IN-2 | 2983117-36-6 | FABP4-IN-2 (Compd 10g) is a selective, orally bioactive FABP4 inhibitor (antagonist) with a Ki of 0.51 μM for FABP4 and a Ki of 33.01 μM for FABP3. | |
V79373 | FABP4-IN-3 | FABP4-IN-3 (compound C3) is a selective FABP4 inhibitor (FABP4 Ki = 25 ± 3a nM, FABP3 Ki = 15.03 μM), which is 601 times more selective than FABP3. | ||
V84099 | FABP4/5-IN-4 | 2862795-48-8 | ||
V84013 | FABP4/5-IN-5 | 2862791-11-3 | ||
V87426 | RO6806051 | 1433901-75-7 | RO6806051 (compound 12) is a potent dual fatty acid binding protein 4 and 5 (FABP4 and FABP5) inhibitor with good selectivity and absorption, distribution, metabolism, and excretion (eADME) properties. |